吉西他滨联合卡培他滨在转移性胰腺癌一线化疗中的疗效及安全性分析

目的分析研究吉西他滨联合卡培他滨在转移性胰腺癌一线化疗中的疗效及安全性。方法 23例初治转移性胰腺癌一线化疗接受吉西他滨联合卡培他滨:吉西他滨1000 mg/m2,静脉滴注30 min,第1、8天;卡培他滨650 mg/m2,2次/天,口服,第1~14天;每3周1个疗程,评价它的总生存、无进展生存、客观缓解率、临床获益率、临床获益反应、糖类抗原19-9(CA19-9)缓解率和不良反应等。结果 23例转移性胰腺癌患者中,4例出现部分缓解,6例获得疾病稳定,13例出现按肿瘤进展,总客观缓解率为17.4%,平均缓解持续时间为6.8个月,临床获益为43.5%,临床获益反应率为52.2%,CA19-9缓解率为65.2%,中位无进展生存为6.1个月,1年无进展生存率14.2%;中位生存时间为7.3个月,1年生存率为25.1%。绝大部分治疗相关不良反应是1至2级,最常见的3/4毒性反应为中性粒细胞减少。结论研究证实吉西他滨与卡培他滨联合方案可成为转移性胰腺癌一线化疗方案之一;同时,临床获益反应在疗效相近的化疗方案的选择上有着重要的指导作用。

Anaysis on the efficacy and safety of gemcittabine combined with capecitabine in the first-line chemotherapy for metastatic pancreatic cancer

Objective To have retrospective analysis on the efficacy and safety of gemcitabine combined with capecitabine in the first-line chemotherapy for metastatic pancreatic cancer. Methods 23 patients with lately diagnosed metastatic pancreatic cancer received gemcitabine plus capecitabine（ oral capecitabine 650 mg/m^2 twice a day for 1 to 14 days plus Gem 1,000 mg/m^2 by 30-minute infusion every 3 weeks）. And the overall survival,progressionfree survival,objective response rate, clinical benefit rate, clinical benefit response, CA19-9 response rate and side effects were evaluated. Results Among the 23 patients with metastatic pancreatic cancer,4 patients had partial remission,and 6 obtained stable disease,with the overall objective response rate being 17.4%, the average duration of response being 6.8 months,clinical benefit rate being 43.5% ,clinical benefit response rate being 52.2% and CA19-9 response rate being 65.2%. Moreover, the average progression-free survival was 6.1 months with 1-year progressionfree survival rate of 14.2%, while the average survival time was 7.3 months with 1-year survival rate of 25.1%. The majority of related adverse events resulted from the treatment was grade 1 or 2 in severity. Conclusion This retrospective study confirms that gemcitabine integrated with capecitabine can be seen as an option of first-line chemotherapy regimes of metastatic pancreatic cancer; and clinical benefit response plays an important role in selecting chemotherapy regimen with similar efficacy.